Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in Novasign to help scale and expand operations. Through this collaboration, Novasign’s unique modeling workflow will be integrated into Repligen’s tangential flow filtration (TFF) systems. This will not only enhance Repligen’s digitalization journey and strengthen its portfolio of process analytical technology (PAT)-enabled systems but also unlock the potential for future advanced AI modeling within Repligen platforms. The end goal is to streamline process development, enable real-time predictive control, and significantly reduce development timelines and costs through the deployment of digital